Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Feb;6(1):79-81.
doi: 10.2174/156720509787313916.

Resurrecting clinical pharmacology as a context for Alzheimer disease drug development

Robert E Becker  1 , Latha K Unni, Nigel H Greig
Affiliations
Review

Resurrecting clinical pharmacology as a context for Alzheimer disease drug development

Robert E Becker et al. Curr Alzheimer Res. 2009 Feb.

Abstract

Commercial priorities have been identified as negative factors in drug development. We trace the problem to inattention to sound clinical pharmacology practices. When properly applied, clinical pharmacology and associated drug development sciences can, hand in hand, facilitate success in commercial drug development.

PubMed Disclaimer

Conflict of interest statement

The authors have received no other funding for this work and have no financial conflicts of interest.

Figures

Figure 1
Figure 1
Predicted CNS membrane bound AChE inhibition after weekly (WD) and daily (DD) dosing of Alzheimer’s disease patients with metrifonate. For comparison data are provided for red blood cell (RBC) AChE inhibition after weekly and daily dosing of Alzheimer’s disease patients with metrifonate.
See this image and copyright information in PMC

Comment on

  • The perils of Alzheimer's drug development.
    Schneider LS, Lahiri DK. Schneider LS, et al. Curr Alzheimer Res. 2009 Feb;6(1):77-8. doi: 10.2174/156720509787313871. Curr Alzheimer Res. 2009. PMID: 19199878 Free PMC article. No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Schneider LS, Lahiri DK. The Perils of Alzheimer’s Drug Development. Curr Alzheimer Res. 2009;6(1):77–8. - PMC - PubMed
    1. Becker RE, Greig NH. Alzheimer’s disease drug development in 2008 and beyond: problems and opportunities. Curr Alzheimer Res. 2008;5(4):346–57. - PMC - PubMed
    1. Becker RE, Greig NH, Giacobini E. Why do so many drugs for Alzheimer’s disease fail in development? Time for new methods and new practices? J Alzheimer Dis. 2008;15(2):303–25. - PMC - PubMed
    1. Greig NH, Sambamurti K, Yu QS, Brossi A, Bruinsma GB, Lahiri DK. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease. Curr Alzheimer Res. 2005;2(3):281–90. - PubMed
    1. Klein J. Phenserine. Expert Opin Investig Drugs. 2007;16(7):1087–97. - PubMed

MeSH terms